PMID- 29972412
OWN - NLM
STAT- MEDLINE
DCOM- 20181022
LR  - 20201209
IS  - 1678-4170 (Electronic)
IS  - 0066-782X (Print)
IS  - 0066-782X (Linking)
VI  - 111
IP  - 1
DP  - 2018 Jul
TI  - Adropin and Irisin in Patients with Cardiac Cachexia.
PG  - 39-47
LID - 10.5935/abc.20180109 [doi]
AB  - BACKGROUND: Cardiac cachexia is an important predictive factor of the reduction 
      in survival of patients with heart failure with reduced ejection fraction. 
      OBJECTIVES: The aims of the present study were to evaluate adropin and irisin 
      levels in cachectic and non-cachectic subjects and the relationships between the 
      levels of these proteins and clinical and laboratory parameters in patients with 
      HFrEF. METHODS: The clinical records of patients who were admitted to the 
      cardiology outpatient clinic for heart failure with reduced ejection fraction 
      were screened. Cachectic patients were identified and assigned to the study group 
      (n = 44, mean age, 65.4 +/- 11.2 y; 61.4% men). Heart failure with reduced ejection 
      fraction patients without weight loss were enrolled as the control group (n = 42, 
      mean age, 61.0 +/- 16.5 y; 64.3% men). The serum adropin and irisin levels of all 
      patients were measured. A p-value < 0.05 was considered significant. RESULTS: 
      Serum adropin and irisin levels were significantly higher in the cachexia group 
      than in the controls (Adropin (ng/L); 286.1 (231.3-404.0) vs 213.7 (203.1-251.3); 
      p < 0.001, Irisin (microg/mL); 2.6 (2.2-4.4) vs 2.1 (1.8-2.4); p = 0.001). Serum 
      adropin and irisin levels were positively correlated with brain natriuretic 
      peptide (BNP) levels and New York Heart Association (NYHA) class and negatively 
      correlated with body mass index (BMI) and serum albumin levels (all p values: < 
      0.001). In a multivariate analysis, adropin was the only independent predictor of 
      cachexia in the heart failure with reduced ejection fraction patients (OR: 1.021; 
      95% CI: 1.004-1.038; p = 0.017). CONCLUSIONS: The results suggest that adropin 
      and irisin may be novel markers of cardiac cachexia in heart failure with reduced 
      ejection fraction patients. Adropin and irisin are related with the severity of 
      heart failure.
FAU - Kalkan, Ali Kemal
AU  - Kalkan AK
AD  - Mehmet Akif Ersoy Thoracic and Cardiovascular Disease Education and Training 
      Hospital, Department of Cardiology, Istanbul, Turkey.
FAU - Cakmak, Huseyin Altug
AU  - Cakmak HA
AD  - Mustafakemalpasa State Hospital, Department of Cardiology, Bursa, Turkey.
FAU - Erturk, Mehmet
AU  - Erturk M
AD  - Mehmet Akif Ersoy Thoracic and Cardiovascular Disease Education and Training 
      Hospital, Department of Cardiology, Istanbul, Turkey.
FAU - Kalkan, Kubra Erol
AU  - Kalkan KE
AD  - Sisli Hamidiye Etfal Education And Research Hospital, Department of Internal 
      Medicine, Istanbul, Turkey.
FAU - Uzun, Fatih
AU  - Uzun F
AD  - Mehmet Akif Ersoy Thoracic and Cardiovascular Disease Education and Training 
      Hospital, Department of Cardiology, Istanbul, Turkey.
FAU - Tasbulak, Omer
AU  - Tasbulak O
AD  - Mehmet Akif Ersoy Thoracic and Cardiovascular Disease Education and Training 
      Hospital, Department of Cardiology, Istanbul, Turkey.
FAU - Diker, Vesile Ornek
AU  - Diker VO
AD  - Mehmet Akif Ersoy Thoracic and Cardiovascular Disease Education and Training 
      Hospital, Department of Biochemistry, Istanbul, Turkey.
FAU - Aydin, Suleyman
AU  - Aydin S
AD  - Firat University, School of Medicine, Department of Clinical Biochemistry, 
      Elazig, Turkey.
FAU - Celik, Ahmet
AU  - Celik A
AD  - Mersin University, School of Medicine, Department of Cardiology, Mersin, Turkey.
LA  - eng
LA  - por
PT  - Journal Article
DEP - 20180702
PL  - Brazil
TA  - Arq Bras Cardiol
JT  - Arquivos brasileiros de cardiologia
JID - 0421031
RN  - 0 (Biomarkers)
RN  - 0 (Blood Proteins)
RN  - 0 (Enho protein, human)
RN  - 0 (FNDC5 protein, human)
RN  - 0 (Fibronectins)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (Peptides)
SB  - IM
CIN - Arq Bras Cardiol. 2018 Jul;111(1):48-49. PMID: 30110044
MH  - Aged
MH  - Biomarkers/blood
MH  - Blood Proteins
MH  - Cachexia/*blood/etiology
MH  - Case-Control Studies
MH  - Female
MH  - Fibronectins/*blood
MH  - Heart Failure/*blood/complications
MH  - Humans
MH  - Intercellular Signaling Peptides and Proteins
MH  - Male
MH  - Middle Aged
MH  - Peptides/*blood
MH  - Ventricular Dysfunction, Left/*blood/complications
PMC - PMC6078358
COIS- Potential Conflict of Interest No potential conflict of interest relevant to this 
      article was reported.
EDAT- 2018/07/05 06:00
MHDA- 2018/10/23 06:00
PMCR- 2018/07/01
CRDT- 2018/07/05 06:00
PHST- 2017/07/09 00:00 [received]
PHST- 2018/01/24 00:00 [accepted]
PHST- 2018/07/05 06:00 [pubmed]
PHST- 2018/10/23 06:00 [medline]
PHST- 2018/07/05 06:00 [entrez]
PHST- 2018/07/01 00:00 [pmc-release]
AID - S0066-782X2018005008103 [pii]
AID - 10.5935/abc.20180109 [doi]
PST - ppublish
SO  - Arq Bras Cardiol. 2018 Jul;111(1):39-47. doi: 10.5935/abc.20180109. Epub 2018 Jul 
      2.